We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News COVID-19 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry

Innovative Molecular Detection System Offers On-Site and Rapid Detection of SARS-CoV-2

By LabMedica International staff writers
Posted on 13 Jan 2021
A compact and robust molecular detection system based on the isothermal DNA/RNA amplification method can provide on-site and rapid detection of SARS-CoV-2, making it ideal for use in airports, sport venues, pharmacies and workplaces due to its simple and fast operation procedure.

The eGGi molecular detection system developed by Winnoz Technology (Taipei, Taiwan) offers an on-site and rapid screening solution for the SARS-CoV-2 virus. By using saliva or swab specimens as sampling and without RNA extraction, the test result can be finalized in 40 minutes for anyone and anywhere. Unlike a central lab model, the eGGi point-of-care testing solution can be applied and deployed quickly, making it more cost-effective and time saving.

Illustration
Illustration

In addition to the eGGi molecular detection system, Winnoz also offers a vacuum assisted fingertip blood collection system named Haiim that is bundled with various testing kits to identify COVID-19 infection. The rapid screening test results can help medical staff to quickly identify the illness and proceed with appropriate treatments. The portable automatic vacuum assisted fingertip blood micro collection device is extremely efficient in comparison to current methods such as needles. The blood collected using Haiim is of sufficient volume to meet the requirements of many testing strips and requires minimal training to operate. Haiim can be applied within COVID-19 vaccine efficacy test sampling, as the blood specimen can be collected at home and sent to laboratories for testing, thus reducing the risk.

"We believe that the COVID-19 screening and vaccination efficacy test would play a more important role as vaccines roll out to bring our life back to normal." said Dr. Joses Hsiung, Winnoz Founder and CEO. "The advent of new technologies and innovations because of the challenges of the ongoing pandemic will push the global healthcare ecosystem to new boundaries. For example, how to deploy and roll out the screening, vaccines and vaccine efficacy testing quickly would be very crucial. eGGi, a rapid and on-site isothermal PCR, is able to support screening for anyone and anywhere, meanwhile Haiim, a unique blood microsampling solution, makes vaccine efficacy test sampling easier and safer."

Related Links:
Winnoz Technology


Latest COVID-19 News